PROGRESS Trial: TAVR Cuts Death/Heart Failure Risk 33% in Moderate Aortic Stenosis
EW sits 27% above its 52-week low of $74.66.
Summary
Edwards' PROGRESS trial hit its primary endpoint: TAVR beat clinical surveillance in moderate aortic stenosis patients with at-risk features, cutting the two-year composite of death or heart failure by 33% relative (16.7% vs 23.9%). Heart failure hospitalizations were roughly halved, 7.4% versus 14.9%. The results were presented at TCT 2026 and published in the New England Journal of Medicine, which gives them the credibility to shift treatment guidelines. The commercial prize is a new patient pool: moderate AS has been managed passively, and 57% of surveillance patients needed valve replacement within two years anyway. One caveat — all-cause mortality was similar between arms, and the SAPIEN 3 use in moderate AS remains investigational, so a label expansion will be needed to monetize it. This lands after a rough October that included an FDA high-risk recall warning on the Commander M delivery systems and the PASCAL tricuspid approval.
At the time of this announcement, EW was trading at $95.17 on NYSE in the Life Sciences sector, with a market capitalization of approximately $54.9B. The 52-week trading range was $74.66 to $96.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.